Daratumumab

CHEBI:CHEBI_754134

Drug Classification

Important Medical Information

⚕️ This information is sourced from ChEBI (Chemical Entities of Biological Interest) database and is intended for educational purposes only.

  • Always consult with a healthcare professional before starting, stopping, or modifying any medication.
  • Side effects may vary and this list may not be comprehensive.
  • Drug interactions may occur with other medications.

Additional Identifiers

🔍 Click on any linked disease name to learn more about the conditions this medication is used to treat, or explore related drug classifications for more information about similar medications.

Additional Attributes

rxcui
2375141
generic_name
daratumumab and hyaluronidase-fihj (human recombinant)
pharm_class
CD38-directed Antibody Interactions [MoA]
product_type
HUMAN PRESCRIPTION DRUG
listing_expiration_date
20251231
dosage_form
INJECTION, SOLUTION, CONCENTRATE
route
INTRAVENOUS
marketing_start_date
20151116
package_marketing_start_date
20151116
marketing_category
BLA
active_ingredient_strength
1800 mg/15mL
nui
N0000192335
pharm_class_cs
Glycoside Hydrolases [CS]
active_ingredient_name
DARATUMUMAB
unii
4Z63YK6E0E
pharm_class_epc
CD38-directed Cytolytic Antibody [EPC]
labeler_name
Janssen Biotech, Inc.
manufacturer_name
Janssen Biotech, Inc.
pharm_class_moa
CD38-directed Antibody Interactions [MoA]
brand_name
Darzalex Faspro
brand_name_base
Darzalex Faspro
product_ndc
57894-503
application_number
BLA761145
spl_id
1f2d1a78-ea5c-9b2a-e063-6294a90ad5d7
package_ndc
57894-503-01
package_description
1 VIAL, SINGLE-DOSE in 1 BOX (57894-503-01) / 15 mL in 1 VIAL, SINGLE-DOSE
spl_set_id
4bb241af-4299-4373-8762-2d6709515db0
upc
0357894503019
22-rdf-syntax-ns#type
http://www.w3.org/2002/07/owl#Class